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Abstract: Family history, which includes both common environmental and genetic effects, 
is associated with an increased risk for many neuropsychiatric diseases. Investigators have 
identiﬁ  ed several disease-causing mutations for speciﬁ  c neuropsychiatric disorders that display 
Mendelian segregation. Such discoveries can lead to more rational drug design and improved 
intervention from a better understanding of the underlying biological mechanisms. However, 
a key challenge of genetic discovery in human complex diseases, including neuropsychiatric 
disorders, is that most diseases with genetic components display non-Mendelian patterns of 
inheritance. Recent advances in human population genetics include high-density genome-wide 
analyses of single nucleotide polymorphisms (SNPs) that make it possible to study complex 
genetic contributions to human disease. This approach is currently the most powerful strategy 
for analyzing the genetics of complex diseases. Genome-wide SNP analyses often require a large 
collaborative effort to collect, manage, and disseminate the numerous samples and correspond-
ing clinical data. In this review we discuss the use of publicly available biorepositories for the 
collection and distribution of human genetic material, associated phenotypic information, and 
their use in genome-wide investigations of human neuropsychiatric diseases.
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Repository science
Technical advances in molecular biology over the past 20 years, including the advent 
of polymerase chain reaction (PCR), the discovery of SNPs as a class of highly variable 
polymorphisms, and the use of multi-well format plates and associated instrumentation 
for many genetic analyses have provided essential building blocks for high-throughput 
genome-wide association studies. However, identifying, consenting and gathering 
relevant clinical information for thousands of individuals are challenging. Distributing 
human genetic materials and associated clinical information poses legal challenges 
and issues related to protection of human subjects. Therefore, collection and distribu-
tion of human biomaterials for genetic research is not an area into which traditional 
US commercial entities have ventured, and the supply of large numbers of genomic 
DNA samples represents a bottleneck. Evidence of the value of readily accessible and 
abundant human DNA comes from the study of the heritability of schizophrenia in 
Iceland. The relative isolation and proximity of Icelandic families with schizophrenia, 
together with their remarkable cooperation and consent, allowed deCODE Genetics to 
perform a genome-wide linkage scan that identiﬁ  ed neuregulin I (NRG1) as a candi-
date gene for schizophrenia (Stefansson et al 2002). However, the speciﬁ  c conditions 
that facilitated this population-based study in the Icelandic community, and thus the 
efforts associated with this study are not readily reproducible in other populations. In 
addition, the samples used in those and most other population-based studies are not Neuropsychiatric Disease and Treatment 2007:3(5) 614
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publicly available. Limited access to such biomaterials and 
the associated clinical data is a large impediment to progress 
in genome-wide analyses of complex diseases, including neu-
ropsychiatric disease. The National Institutes of Health and 
other contracting agencies have addressed the need for such 
biomaterials by funding non-proﬁ  t repositories to receive, 
manage and distribute human biomaterials.
Repositories that generate and store human cell lines, 
and the genomic DNA derived from these cell lines, rely 
on an approach that was developed over 30 years ago in 
which Epstein-Barr virus (EBV) infects and transforms B 
lymphocytes present in whole blood (Yata et al 1975). The 
transformed lymphoblasts from each individual subject 
represent a renewable source of genetic material. Both the 
lymphoblasts and the DNA can be distributed to investiga-
tors, and in the case of public repositories, these materials are 
a valuable resource for the biomedical research community 
at large. Additionally, in some cases the availability of cell 
lines with associated genotypic and phenotypic information 
represents a second-generation resource for mRNA- and 
protein-expression analyses and other cell-based studies 
aimed at follow-up of genetic “hits”. This strategy employs 
biomaterials for gene discovery, ie, the transformed lym-
phoblasts from which subject DNA is extracted, as a tool for 
further investigating the biological signiﬁ  cance of candidate 
gene variation.
Consent and patient protection
The ﬁ  rst critical step in designing a successful genome-wide 
association study involves the collection of human bioma-
terial, most often a peripheral blood specimen. This step 
requires oversight by an Institutional Review Board (IRB) 
and creation and use of an Informed Consent document. 
When developing such a document for a genetic study there 
are three primary ethical issues related to the use of specimens 
and associated private medical information (PMI) in research. 
The ﬁ  rst is the protection of individuals who have contributed 
their samples or data from research risks and to weigh these 
risks with the potential beneﬁ  ts. The principal risk to subjects 
is the potential breach of privacy and conﬁ  dentiality, with 
additional risks being psychosocial harms from research or 
research ﬁ  ndings, and physical risks from procedures for 
collecting specimens, such as biopsies or blood draws. The 
relative beneﬁ  ts to society need to be considered explicitly 
when establishing population-based genetic research studies 
that are unlikely to lead to direct beneﬁ  t for any individual 
human subject. The second major ethical issue is respect for 
persons; this includes respect for individuals and groups of 
individuals and the autonomy of these individuals to make 
decisions about the use and disposition of their samples and 
data. Attending to respect for persons should be considered 
independently of the need to evaluate and minimize risks; 
subjects may have values or beliefs in relation to uses of 
samples and data that are not directly linked to concerns about 
risk. The third ethical issue is the importance of ensuring the 
responsible use of valuable research resources to advance 
scientiﬁ  c knowledge about human health for the beneﬁ  t of 
society. The research community must engage in an open 
and continual dialog regarding the responsible use of human 
genetic materials. It is wise to create an infrastructure by 
which biomaterials can be collected and distributed respon-
sibly, with minimal barriers to research or inordinate costs 
that prevent societal investment in research from yielding 
beneﬁ  ts to human health.
In some cases there may be risks to social groups or com-
munities due to the release of aggregate research ﬁ  ndings 
that can cause anxiety, stigma, or economic consequences, 
even when no individually identiﬁ  able information has been 
revealed. In such cases community consultation may be 
appropriate. For example, it may be appropriate to include a 
community representative on an advisory or oversight board 
for the repository, or other extensive consultations may be 
undertaken in advance of initiating a research project that 
focuses on a particular population.
In all cases the collection, storage, distribution and use of 
human specimens and data should be conducted in accordance 
with all applicable regulations. These include 45 Code of 
Federal Regulation (CFR) part 46, the Food and Drug Admin-
istration human subjects regulations 21 CFR part 50 and 56, 
and 812; the Health Insurance Portability and Accountability 
Act (HIPAA) Privacy and Security Rules (45 CFR Parts 160 
and 164). There are also state and local laws, such as laws 
governing genetic testing, regulating genetic information 
and medical records privacy that must be considered when 
designing a genetic study of human subjects.
It is noteworthy that under 45 CFR 46, research use of spec-
imens and data that are not readily identiﬁ  able, and for which 
there are no links to individually identifying information, is not 
considered to be human subjects research. Additionally, some 
repositories, such as those funded by the National Institutes of 
Health, are contracts to non-billable entities, ie, entities that 
do not provide clinical care, and in those cases, the HIPAA 
Privacy Rule does not apply. Nonetheless, HIPAA compliance 
is worthwhile, as most of the specimens are likely to originate 
at sites that are billable entities. Repositories should consider 
how the HIPAA Privacy Rule may apply to the collection Neuropsychiatric Disease and Treatment 2007:3(5) 615
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and use of any individually identiﬁ  able information that is 
particular to their repository operations [for further informa-
tion, see: “NIH: Research Repositories, Databases and the 
HIPAA Privacy Rule” issued July 2, 2004 (http://privacyru-
leandresearch.nih.gov/research_repositories.asp) and “OHRP: 
Guidance on Research Involving Coded Private Information or 
Biological Specimens”, issued August 10, 2004 (http://www.
hhs.gov/ohrp/humansubjects/guidance/cdebiol.pdf)].
Sufﬁ  cient sample size to address 
complex genetic risk
How many subjects are needed for neuropsychiatric disease 
gene discovery? The answer to that question depends on 
several factors, including the genetic architecture (number 
of genes, their effects, and interactions with other genes and 
environmental risk factors), potential disease heterogeneity 
(genetic and environmental), and proposed study design. 
Because we do not know the number of loci involved in 
most neuropsychiatric disease etiology, nor do we know 
their population prevalence and penetrance, the number 
of subjects needed cannot be precisely predicted. Many 
diseases, including neuropsychiatric disease, have multiple 
clinical proﬁ  les that may reﬂ  ect differences in underlying 
pathogenesis. Sub-populations or strata deﬁ  ned by gender, 
age of onset, race, ethnicity, are all potentially valuable clas-
siﬁ  cation variables. However, the more stratiﬁ  ed a popula-
tion of samples, the larger the sample size needed for study 
(Wang et al 2005).
In the case of Parkinson’s disease (PD), there are exam-
ples of disease-causing alleles that are inherited in a Mende-
lian fashion (Simon-Sanchez et al 2005; Mizuno et al 2006), 
but these do not represent the majority of cases (see reviews 
(Gwinn-Hardy 2002, Wood-Kaczmar et al 2006). Substantial 
statistical genetic and empirical data suggest that 5,000 PD 
cases would be sufﬁ  cient for discovery of individual gene 
effects underlying risk of complex human disease under most 
genetic models with 80% statistical power. Banking speci-
mens from a minimum of 2,000 cases allows identiﬁ  cation of 
SNPs with approximately a 1.5-fold or greater relative risk. 
For common SNPs (with minor allele frequency 10%), 
this represents an allele frequency difference of at least 
10%. In addition, replication of the experimental ﬁ  ndings 
depends upon the availability of populations independent 
of the original cohort.
To design a study capable of detecting gene-gene or 
gene-environment interactions, the sample size required 
to maintain power would be increased by at least 4-fold. 
Thus, there is a clear rationale and need for large specimen 
collections. Public availability of such biomaterials is vital 
for accelerating the rate at which large-scale genetic studies 
can reach sufﬁ  cient power to detect disease-causing genes 
and interacting loci.
Collecting clinical data
The quality of genotype-phenotype characterizations involv-
ing many thousands of samples acquired over a period of 
years depends on the quality of phenotypic deﬁ  nitions, 
uniform data acquisition, and rigorous data management. 
Standardized clinical criteria are essential to a large-scale 
sample comparison within and across clinical collection sites. 
Furthermore, use of these criteria can allow stratiﬁ  cation 
by associated traits (endophenotypes or sub-phenotypes). 
Fortunately, in the neuropsychiatric disease community, 
a large number of clinical trials have accustomed many 
clinicians to standardized clinical criteria, thus facilitating 
collection of large, well-characterized populations. Also, the 
strong clinical tradition in neuropsychiatric disease sets a 
foundation for pharmacogenetic studies, and, when possible, 
pharmacological response or signiﬁ  cant exposure should be 
included in clinical datasets. Additionally, well-designed 
collections of control subjects are crucial and in some cases 
may allow for the use of control subjects for multiple neuro-
psychiatric disorders. This is particularly important because 
most genome-wide association studies (GWAS) use the 
case/control paradigm. Identifying and enrolling large num-
bers of control subjects in these studies requires signiﬁ  cant 
dedication and application by a collaborative team. This is 
due to the fact that “apparently healthy”, “neurologically 
normal” individuals, who would be suitable for use as control 
subjects, are not likely to be seen in clinical neurology and 
clinical neuropsychiatric settings. Some case/control studies 
utilize unaffected spouses as control subjects in part due to 
their accessibility and to the fact that they are likely to share 
some environmental exposure history.
It is unlikely that individual researchers are capable of 
enrolling the large number of subjects necessary for GWAS   
of complex diseases. In addition, the most appropriate sub-
jects for genetic studies are sometimes those who are the most 
difﬁ  cult to enroll. “Typical” sporadic cases of a disease are 
often desirable in GWAS, yet these are the cases that are least 
likely to present in a subspecialty clinic. Therefore, a major 
collaborative effort involving a large number of clinicians 
is often required to enroll sufﬁ  cient subjects for successful 
GWAS. An approach that has been used successfully in the 
cancer research community is one in which private practi-
tioners that enroll subjects maintain an academic interest Neuropsychiatric Disease and Treatment 2007:3(5) 616
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and involvement in the collaborative project (Kaluzny et al 
1993). This approach has catalyzed the expansion of cancer 
clinical trials to include a much broader and larger collection 
of patients. In 2003, the National Cancer Institute proposed 
a framework for NCI-funded large-scale biospecimen and 
data collection and distribution entitled, The National Bio-
specimen Network Blueprint (http://prostatenbnpilot.nci.nih.
gov/FINAL_NBN_Blueprint.pdf).
Using the experiences gained from the structure of NIH-
funded cancer clinical trials networks, the Clinical Research 
Collaboration (CRC) at the National Institute of Neurological 
Disorders and Stroke (NINDS) has undertaken a project to 
develop of an infrastructure to efﬁ  ciently execute NINDS-
sponsored clinical research (see http://www.ninds.nih.
gov/news_and_events/proceedings/2002_clinical_research_
workshop.htm). The CRC was established to expedite subject 
recruitment; it involves a wide spectrum of investigators, 
including practicing physicians. The involvement of the 
clinic-based neurologist has the additional beneﬁ  t of making 
participation in NINDS-sponsored clinical research more 
accessible to patients. One of the projects that utilizes the 
CRC initiative enrolls subjects and collects specimens to 
build a sizeable, well-characterized cohort with which to per-
form GWAS of neuropsychiatric disorders. Additionally, the 
CRC at NINDS aims to engender a tradition of participation 
in clinical research and to educate primary physicians regard-
ing neurogenetics research. The NINDS Human Genetics 
Repository (http://ccr.coriell.org/ninds), established in 2002, 
beneﬁ  ts from the CRC Sample Collection and Submission 
Study. The Repository, located at the Coriell Institute for 
Medical Research, currently has specimens from over 14,000 
subjects, over 4,000 of which are already publicly available, 
including those with Parkinson’s disease, epilepsy, cerebro-
vascular disease and motor neuron diseases. The NINDS 
Repository has detailed neuropsychiatric clinical data both 
for cases and controls. In addition, The NINDS Repository is 
similar in framework and management of processes, quality 
and data to the large-scale system of biospecimen and data 
collection and distribution proposed in the NBNB.
Bioinformatics
The utility of a sample biorepository used for GWAS is 
maximized by a scalable and extensible informatics infra-
structure. The information management system should meet 
the requirements of real-time data capture, collection site 
management, chain of custody handling, and operational 
efﬁ  ciency for a large number of samples, each of which is 
linked to individual data. Moreover, as an integrated solu-
tion, the system must manage the genotypic and phenotypic 
data associated with biospecimens under compliance with 
all relevant privacy laws.
The information systems design must not only consider 
the quality but also the accessibility of the biospecimens 
and associated data. The system should have the ability to 
integrate with other databases as both a source and a recipi-
ent of data. For example, the informatics infrastructure of 
the NINDS Human Genetics Repository provides open, 
internet-based access to both phenotypic and genotypic data 
in several data formats, such as comma-separated values 
text, Excel, and XML. Additionally, curated links to external 
data sources such as the dbSNP (http://www.ncbi.nlm.nih.
gov/SNP) and Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo) supplements the information available 
about the biospecimens. The scale of GWAS in complex 
human disorders demands that the data management system 
be secure, robust, and ﬂ  exible in order to accommodate the 
complex and collaborative nature of such projects.
The future
The cost of high-throughput genome-wide SNP genotyping 
is approaching less than 1 cent per genotype, and public 
application of genome-wide SNP analysis has begun in 
earnest. Biorepositories that can supply large numbers 
of human specimens and associated clinical datasets are 
becoming increasingly important to the advancement of 
translational research and to the achievement of improved 
medical care.
Other federally-funded repositories have focused on col-
lections of specimens for distinct missions. For example, one 
of the oldest NIH-funded repositories, the National Institute 
of General Medical Sciences (NIGMS) repository (http://ccr.
coriell.org/nigms), collects biomaterials from subjects with a 
large number of genetic conditions, many of them displaying 
Mendelian inheritance. Structurally, this type of repository 
tends to be built from many non-interacting individual col-
lection sites, rather than from multiple interacting sites and 
to have a small number of specimens from each of a large 
number of disorders. Collections such as these continue to 
be integral to the success of research aimed at identifying 
disease-causing mutations for Mendelian disorders (eg, 
Kapetanaki et al 2006; Matsuura et al 2006; Rivolta et al 
2006). Most recently, the National Human Genome Research 
Institute (NHGRI) established a cell repository (http://ccr.
coriell.org/nhgri) aimed at banking NHGRI-sponsored proj-
ects, including the International HapMap Project specimens. 
These samples are being collected from distinct populations Neuropsychiatric Disease and Treatment 2007:3(5) 617
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for studies of human genetic variation and are associated with 
no clinical information.
Additionally, other NIH-funded repositories are collecting 
samples for large-scale studies aimed at identifying genes that 
have a complex non-Mendelian inﬂ  uence on susceptibility. 
Included in this group are those dedicated to banking samples 
for the study of a number of neurological disorders (http://
neuroscienceblueprint.nih.gov/neuroscience_resources/cell_
tissue.htm). The National Heart Lung and Blood Institute 
(NHLBI)-sponsored Framingham Heart Study, established 
50 years ago to investigate cardiovascular disease by collect-
ing general medical information on a population of individu-
als from Framingham, Massachusetts (Namboodiri 1984) 
expanded its goals in recent years to include genetic studies 
and offers DNA from individuals with associated medical 
information to researchers. One of the ﬁ  rst biorepositories to 
make genome-wide genotyping data completely and publicly 
accessible, in combination with detailed clinical data, is the 
NINDS Human Genetics Repository in collaboration with 
researchers at the NIA (see Fung et al 2006). This genotype/
phenotype dataset (https://queue.coriell.org/Q/snp_index.
asp), initially posted in March 2006, has generated con-
siderable interest in the scientiﬁ  c community, having been 
accessed by researchers from across the globe more than 
560 times. The Wellcome Trust Case Control Consortium 
(WTCCC), made up of 24 United Kingdom(UK)-based 
geneticists, is performing high-density SNP genotyping on 
2000 cases for each of 7 diseases along with a common set of 
3000 controls (1500 from the 1958 British Birth Cohort and 
1500 UK Blood donors); similar analyses in four additional 
disease groups are planned. Genotype and phenotype data 
are stored at WTCCC database. Access to data and materi-
als will be considered by an independent access committee 
6 months after completion of the study (http://www.wtccc.
org.uk/info/overview.shtml).
In 2006, the NIH launched two large GWAS initiatives 
with open access to genotype data at their core. The ﬁ  rst, 
Genetic Association Information Network or GAIN, was 
established in 2006 through a public/private partnership 
between the Foundation of the National Institutes of Health, 
Pﬁ  zer Global Research and Development, Perlegen Sciences, 
Affymetrix Inc. and the Broad Institute; currently, it funds six 
studies aimed at determining the genetic factors that inﬂ  uence 
susceptibility to psoriasis, attention deﬁ  cit hyperactivity dis-
order, schizophrenia, bipolar disorder, major depression and 
type 1 diabetes in a total of 18,000 individuals. High-density 
SNP genotype information is housed in a database managed 
by the National Center for Biotechnology Information (NCBI) 
and is available to the research community (http://www.ncbi.
nlm.nih.gov/WGA/programs/GAIN). The second, Cancer 
Genetic Markers of Susceptibility or CGEMS, is funded by 
the National Cancer Institute, and is aimed at determining 
the genetic factors that inﬂ  uence susceptibility to breast and 
prostate cancer (http://cgems.cancer.gov). The data generated 
is made publicly available at the Cancer Biomedical Informat-
ics Grid (caBIG) (http://caintegrator.nci.nih.gov/cgems). The 
ﬁ  rst signiﬁ  cant ﬁ  nding of this initiative is the identiﬁ  cation of 
a new prostate cancer susceptibility locus as well as conﬁ  rma-
tion of a previously identiﬁ  ed locus, both on Chromosome 8 
(Yeager et al 2007).
The role of gene dosage has been shown to be an 
important causal factor in neurological disorders, including 
Alzheimer’s and Parkinson’s disease (eg, Martins et al 2005, 
Bonifati et al 2005). Also, there is renewed interest in copy 
number variation and its inﬂ  uence on human disease (Khaja 
et al 2006; Redon et al 2006; White and den Dunnen 2006) 
including neuropsychiatric disease (eg, Eriksen et al 2005; 
Nishioka et al 2006) as well as its role in pharmacogenomics 
(eg, Ouahchi et al 2006). This work is supported by new 
approaches for measuring such variation (Fiegler et al 2006; 
Ragoussis et al 2006; Tchinda and Lee 2006). Recently, the 
use of genome-wide SNP genotyping has been shown to 
increase the potential to augment or replace current methods 
aimed at defining chromosomal abnormalities (Simon-
Sanchez et al 2006). Public availability of genome-wide SNP 
genotyping will greatly facilitate the rapid accumulation of 
equivalent data to produce an encyclopedia of normal and 
abnormal structural genomic variation, similar to previous 
efforts for gross chromosomal abnormalities (Mitelman 
1998), in addition to enabling standardized cross-comparison 
among laboratories.
Summary
In summary, the field of neuropsychiatric disease has 
entered an era of complex gene discovery research. As with 
all genome-wide approaches to complex disease, there are 
continued challenges regarding determination of optimal 
sample sizes for affected and control populations. It is clear 
that biorepositories play an important role in this effort. Such 
repositories, involved in the collection and dissemination 
of specimens and associated data, must supply high quality 
biomaterials and implement powerful data management and 
bioinformatics tools to meet the needs of a complex collab-
orative network of collection sites and scientists. Currently, 
this niche is being ﬁ  lled in large part by federally-sponsored 
repositories with distinct scientiﬁ  c missions, but a shared Neuropsychiatric Disease and Treatment 2007:3(5) 618
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interest in supporting collaborative research and public avail-
ability of data. There is the potential for participation by the 
commercial sector, speciﬁ  cally the pharmaceutical industry, 
in such large-scale efforts aimed at improving human health. 
However, the societal investment in population-based studies 
of complex disease, including neuropsychiatric disease, is best 
served by repositories that offer broad access to results and 
material that can propel these efforts from bench to bedside.
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